Hemoglobin A1C (HbA1C) Testing

Global Hemoglobin A1C (HbA1C) Testing Market to Reach US$2.3 Billion by 2030

The global market for Hemoglobin A1C (HbA1C) Testing estimated at US$1.5 Billion in the year 2024, is expected to reach US$2.3 Billion by 2030, growing at a CAGR of 8.1% over the analysis period 2024-2030. Ion-Exchange High Performance Liquid Chromatography (HPLC), one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$915.7 Million by the end of the analysis period. Growth in the Immunoassays segment is estimated at 9.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$422.0 Million While China is Forecast to Grow at 10.6% CAGR

The Hemoglobin A1C (HbA1C) Testing market in the U.S. is estimated at US$422.0 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$274.2 Million by the year 2030 trailing a CAGR of 10.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.2% and 8.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.

Global Hemoglobin A1C (HbA1c) Testing Market - Key Trends & Drivers Summarized

Hemoglobin A1C (HbA1c) testing is a crucial diagnostic tool for managing diabetes, providing a long-term indicator of blood glucose levels over the past two to three months. Unlike regular blood glucose tests that measure a snapshot of current blood sugar levels, HbA1c tests reflect the average blood glucose levels by measuring the percentage of glycated hemoglobin in the blood. This test is essential for diagnosing diabetes, assessing the effectiveness of treatment plans, and making necessary adjustments to medication or lifestyle. It helps healthcare providers and patients monitor glycemic control more effectively, thereby reducing the risk of diabetes-related complications.

The importance of HbA1c testing in diabetes management cannot be overstated, as it provides comprehensive insights into how well a patient`s blood sugar levels are being managed over time. The test is typically recommended every three to six months for individuals with diabetes, but it is also used for screening and diagnosing prediabetes and diabetes in the general population. Advances in testing technology have made HbA1c tests more accurate, accessible, and convenient, with point-of-care testing devices enabling quicker results in clinical settings. Additionally, home testing kits have become available, empowering patients to monitor their condition more proactively.

The growth in the Hemoglobin A1C (HbA1c) testing market is driven by several factors. Firstly, the rising prevalence of diabetes worldwide is increasing the demand for regular HbA1c testing to manage and diagnose the condition effectively. Secondly, advancements in diagnostic technology are making HbA1c tests more accurate and accessible, enhancing their adoption in both clinical and home settings. Thirdly, the growing emphasis on preventive healthcare and early diagnosis of diabetes is driving the market for HbA1c testing as a key component of diabetes management programs. Lastly, increasing awareness and education about diabetes and its complications are encouraging more frequent and consistent testing among at-risk populations. These factors collectively ensure the continued growth and importance of the HbA1c testing market.

SCOPE OF STUDY:

The report analyzes the Hemoglobin A1C (HbA1C) Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Technology (Ion-Exchange High Performance Liquid Chromatography (HPLC), Immunoassays, Boronate Affinity Chromatography, Direct Enzymatic Assays, Other Technologies); End-Use (Hospitals & Clinics, Diagnostic Laboratories, Other End-Uses)

Geographic Regions/Countries:
World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 110 Featured) -

• Abbott Laboratories, Inc.
• Beckman Coulter, Inc.
• Bio-Rad Laboratories, Inc.
• ACON Laboratories, Inc.
• ARKRAY, Inc.
• A. Menarini Diagnostics Srl
• Apex Biotechnology Corporation
• Axis-Shield Diagnostics Ltd.
• Agappe Diagnostics Ltd.
• Biorex Diagnostics
• Boditech Med, Inc.
• Biosurfit SA
• Accruex Biomedical Pvt., Ltd.
• Ailex Technology Group Co., Ltd.
• American Screening Corporation, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.